First Light (FLAG) announced this morning that it has secured $25 million in additional funding for its combination with clinical-stage drug developer Calidi Biotherapeutics.
The investment is to be led by Jackson Investment Group, which has put forward $5 million as the first stage of a Series B. The remaining $20 million is conditioned upon Calidi closing its combination with First Light and includes some promote shares as an inducement to investors from First Light’s sponsor and Metric Finance Holdings.
The combination did not previously include committed capital provisions, but the parties noted they would seek out a $40 million PIPE at announcement.
The new cash also brings Calidi closer to where it was in a previous SPAC deal announced with EDOC Acquisition Corp. (NASDAQ:ADOC) in March 2022. This included a $25 million PIPE, a $10 million backstop and later a $75 million stock purchase agreement, but it was terminated in August 2022.
Calidi’s new $335 million combination with First Light was announced in January with at a -25% valuation cut from the EDOC deal. But, the new committed capital is nonetheless expected to advance its CLD-101, CLD-201, and CLD-202 drug candidates, which deliver oncolytic viruses for targeted therapy against difficult-to-treat cancers.
At the SPAC of Dawn Coinbase (NASDAQ:COIN) notched a surprise profit of over $1.5 billion in the first quarter of 2024, well exceeding estimates, demonstrating the powerful effect of publicly traded ETFs have had on crypto marketplaces since the start of the year. The result has pushed the company to bump up its own guidance...
Online casino and sports company Rush Street (NYSE:RSI) is up +18.4% in trading today on the back of a solid first quarter earnings release, bringing the company’s stock to its highest price since the second half of 2022 (currently $7.60). This makes it the latest in a line of 2020 and 2021 de-SPACs that have...
Mountain Crest V (NASDAQ:MCAG) broke a long dealmaking silence by SPACs this morning, albeit with a non-binding agreement to combine with Seoul-based diagnostic biotech firm CUBEBIO. The term sheet would give the company a $620 million pre-transaction equity value and help accelerate the rollout of CUBEBIO’s CEED-NOVUS cancer screening kit products. The company signed an...
Churchill Capital Corp IX (NASDAQ:CCIXU) announced the pricing of its $250 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CCIXU”, Thursday, May 2, 2024. The new SPAC will conduct a broad search and has not limited itself to any particular sector or focus, but it plans to...
At the SPAC of Dawn Layoffs in the tech sector ticked down in March to 7,322, making it the most merciful period of 2024 so far for tech workers after back-to-back months that saw nearly 35,000 let go in total, according to Layoffs.fyi. The dip could be an indication that the contraction in tech funding...